Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Chengdu Di'Ao Jiuhong Pharmaceutical Factory has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 3 actions are assigned to 3 distinct examiners. These examiners are situated within 2 distinct art units, indicating some concentration of technical review within the USPTO's pharmaceutical examination divisions. This arrangement may lead to some consistency in the types of rejections or requirements issued across the cases.
PECKHAM, RICHARD GRANT is the busiest examiner, managing 1 busiest examiner pending office action. Since the 3 pending office actions are split among 3 distinct examiners, no single person controls the majority of the workload. However, the 2 distinct art units suggest that at least two of the 3 distinct examiners are working within the same specialized group. Practitioners should monitor the 2 distinct art units for shared examination patterns that could influence the strategy for all 3 pending office actions.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| §112 only | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PECKHAM, RICHARD GRANT | 1 | 68.1% | +35.1% |
| ANDERSON, REBECCA L | 1 | 73.4% | +23.6% |
| WILSON, JERICA KATLYNN | 1 | 61.4% | +39.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18011757 | ARYL PHOSPHOROUS OXIDE COMPOUNDS AND USE THEREOF | WILSON, JERICA KATLYNN | 56d overdue |
| 18834161 | Benzimidazole Or Azabenzimidazole Compound, Preparation Method Therefor And Use Thereof | PECKHAM, RICHARD GRANT | — |
| 18682185 | Crystal Forms, Preparation Method And Application Of Aryl Phosphine Oxide Compound | ANDERSON, REBECCA L | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18834161 | Benzimidazole Or Azabenzimidazole Compound, Preparation Method Therefor And Use Thereof | PECKHAM, RICHARD GRANT | — | §112 | Non-Final OA | — | Pending | Jul 29, 2024 |
| 18682185 | Crystal Forms, Preparation Method And Application Of Aryl Phosphine Oxide Compound | ANDERSON, REBECCA L | 1626 | §112 | Non-Final OA | — | Pending | Feb 08, 2024 |
| 18011757 | ARYL PHOSPHOROUS OXIDE COMPOUNDS AND USE THEREOF | WILSON, JERICA KATLYNN | 1621 | §103 | Non-Final OA | 56d overdue | Pending | Dec 20, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial